Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — CHI Family Conference 2021
12 slides from Crinetics Pharmaceuticals's conference presentation, Jun 5, 2021
Slide 1: CRN04777: A Selective SST5 Agonist for the Treatment of Hyperinsulinism
CRN04777: A SELECTIVE SST5 AGONIST FOR THE TREATMENT OF HYPERINSULINISM 05 June 2021 CHI Family Conference CONFIDENTIAL
Slide 2: Crinetics: Who We Are & What We Do
Crinetics: Who We Are & What We Do CONFIDENTIAL CRINETICS PHARMACEUTICALS | 2
Slide 3: Our Mission
Our Mission: To build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives CONFIDENTIAL CRINETICS PHARMACEUTICALS | 3
Slide 4: Insulin Secretion: Inside the pancreatic beta-cell
Insulin Secretion: Inside the pancreatic beta-cell KATP Under normal conditions glucose channel depolarize and insulin are tightly coupled Glucose Energy (ATP) Calcium channel SST2 Somatostatin receptor (sst) INSULIN SST5 INSULIN CONFIDENTIAL CRINETICS PHARMACEUTICALS | 4
Slide 5: Insulin Secretion: Inside the pancreatic beta-cell
Insulin Secretion: Inside the pancreatic beta-cell A less well-known hormone KATP channel depolarize called somatostatin can turn Glucose Energy off insulin secretion at one of (ATP) the last steps Calcium channel SST2 Somatostatin X receptors INSULIN SST5 somatostatin (blocks later steps) CONFIDENT
Slide 6: Insulin Secretion: What happens in Congenital Hyperinsulinism?
Insulin Secretion: What happens in Congenital Hyperinsulinism? Genetic mutations in KATP channel depolarize Congenital HI, lead to insulin Glucose Energy secretion continues even (ATP) when glucose is low Calcium channel SST2 Somatostatin receptors INSULIN SST5 INSULIN CONFIDENTIAL CRINETICS PHARMAC
Slide 7: Now what? What can we do?
Now what? What can we do? Diazoxide (blocks KATP channel) Diazoxide is the only KATP channel approved drug Glucose Energy (ATP) X • Blocks the KATP channel • Efficacy dependent on Calcium channel genetic mutation SST2 (ineffective in ~50% of Somatostatin receptors INSULIN patients) SST5 • Even those
Slide 8: Now what? What can we do?
Now what? What can we do? Somatostatin receptor agonists KATP channel depolarize (activates the receptor) Glucose Energy (ATP) • Blocks later steps of insulin secretion Calcium • Not genetics dependent channel SST2 Octreotide X • Octreotide acts on SST2 INSULIN • Injectable and not for very SST5 you
Slide 9: Now what? What can we do?
Now what? What can we do? Somatostatin receptor agonists KATP channel depolarize (activates the receptor) Glucose Energy (ATP) • Blocks later steps of insulin secretion Calcium • Not genetics dependent channel SST2 Octreotide X • Octreotide acts on SST2 INSULIN • Injectable and not for very SST5 you
Slide 10: So where are we? What's next?
So where are we? What’s next? • CRN04777 has received both US Rare Pediatric Disease and EU Orphan Drug Designations • CRN04777 is in the middle of a Phase 1 study in healthy adults Make sure it’s safe! Make sure it works! • Data soon!!! CONFIDENTIAL CRINETICS PHARMACEUTICALS | 10
Slide 11: Working together CHI
Working CRN04777 is growing up and needs www.hyperinsulinism.com a name! together CHI We want to include all CHI families! Families & Details are coming soon! Check us out! Visit www.hyperinsulinisim.com to sign up for notifications CONFIDENTIAL CRINETICS PHARMACEUTICALS | 11
Slide 12: CONFIDENTIAL CRINETICS PHARMACEUTICALS | 12
CONFIDENTIAL CRINETICS PHARMACEUTICALS | 12
Crinetics Pharmaceuticals — CHI Family Conference 2021 on 6ix